Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

Oral retinoids can cause side effects ranging from mild to severe, including birth defects, and require careful monitoring and contraception.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.

This study found that mirex and TPA promote papilloma formation in CD-1 mouse skin through distinct populations of mutant Ha-ras cells, resulting in additive tumor yields.

This review synthesizes information on isotretinoin’s systemic toxicity, emphasizing that its adverse effects, including mucocutaneous, hepatic, and musculoskeletal reactions, primarily reflect its pharmacodynamic actions and are generally manageable with individualized dosing and monitoring, though its teratogenicity remains a significant safety concern.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.

This study found that ketorolac tert-butyl ester enhances skin permeation and follicular absorption compared to ketorolac, highlighting the role of lipophilicity and solubility in prodrug design.

This communication reports previously unreported side effects, severe bullous dermatosis and onycholysis, in three patients undergoing high-dose methotrexate and leucovorin calcium therapy, impacting their chemotherapy schedules.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

This study found that cromakalim and pinacidil significantly inhibited porcine detrusor muscle contractions, suggesting these ATP-sensitive potassium channel openers may have potential in treating certain bladder diseases.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

This review of the Motherisk Program's counseling experience found a scarcity of information on medication safety related to paternal exposure to drugs and chemicals during the peri-conception period, emphasizing the need for further research.

This report verifies isotretinoin's significant efficacy in treating severe acne over the past year in the U.S., highlighting the need for careful patient selection and monitoring due to potential side effects.

The researchers found that inhibiting soluble epoxide hydrolase, either genetically or pharmacologically, delayed the onset of chemically induced seizures related to GABA antagonism in experimental models.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This case report highlights a rare instance of severe multi-organ involvement following a single dose of methotrexate for ectopic pregnancy, requiring intensive care but ultimately successfully treated with leucovorin and supportive care.

In this study on mice, a hydro-alcoholic solution containing kopexil significantly enhanced hair growth and increased hair-promoting factors without causing notable liver or kidney toxicity compared to minoxidil.

In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.

This systematic review reports that there is currently no evidence supporting methotrexate for maintaining remission in ulcerative colitis; further large-scale trials are needed to assess its efficacy and safety.

This chapter reviews dermatological drugs and cosmetics, identifying common allergens and preservatives linked to contact dermatitis without reporting new clinical results.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.